Literatur
-
1
Dormandy J A, Charbonnel B, Eckland D J. et al .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet.
2005;
366
1279-1289
-
2
Eckert S, Erdmann E, Lundershausen R. et al .
Konsensuspapier Pioglitazon in DMW.
DMW.
2007;
132
2650-2653
-
3
Home P D, Pocock S J, Beck-Nielsen H. et al .
Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis.
N Engl J Med.
2007;
357
28-38
-
4
Kahn S E, Haffner S M, Heise M A. et al .
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
N Engl J Med.
2006;
355
2427-2443
-
5
Lago R M, Singh P P, Nesto R W.
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lancet.
2007;
370
1129-1136
-
6
Lincoff A M, Wolski K, Nicholls S J, Nissen S E.
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
JAMA.
2007;
298
1180
-
7
Rosen C J.
The rosiglitazone story - lessons from an FDA Advisory Committee meeting.
N Engl J Med.
2007;
357
844-846
-
8
Rottlaender D, Michels G, Erdmann E. et al .
Therapie mit Glitazonen.
DMW.
2007;
132
2629-2632
-
9
Yki-Jarvinen H.
The PROactive study: some answers, many questions.
Lancet.
2005;
366
1241-1242
Prof. Dr. med. Torsten StrohmeyerLeiter Forschung & Medizin
Dr. med. Daniela SeidelLeiterin Fachbereich Innere Medizin
GlaxoSmithKline GmbH & Co. KG
Theresienhöhe 11
80339 München
Phone: 089/8936044-0
Fax: 089/8936044-8000
Email: Daniela.Seidel@gsk.com
